X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4834) 4834
Book Review (1074) 1074
Publication (392) 392
Conference Proceeding (173) 173
Book Chapter (12) 12
Dissertation (4) 4
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nivolumab (4410) 4410
oncology (2754) 2754
index medicus (2532) 2532
immunotherapy (2249) 2249
humans (1987) 1987
ipilimumab (1513) 1513
pembrolizumab (1461) 1461
cancer (1428) 1428
melanoma (1361) 1361
chemotherapy (1060) 1060
docetaxel (982) 982
open-label (850) 850
male (838) 838
female (812) 812
metastasis (764) 764
lung cancer (756) 756
care and treatment (728) 728
middle aged (707) 707
pd-1 (678) 678
patients (673) 673
aged (672) 672
survival (665) 665
tumors (653) 653
immunology (648) 648
safety (642) 642
therapy (554) 554
antibodies, monoclonal - therapeutic use (529) 529
pd-l1 (528) 528
blockade (515) 515
cancer therapies (499) 499
respiratory system (498) 498
metastatic melanoma (495) 495
immune checkpoint (486) 486
cell lung-cancer (464) 464
programmed cell death 1 receptor - antagonists & inhibitors (461) 461
apoptosis (444) 444
clinical trials (443) 443
adult (438) 438
antineoplastic agents - therapeutic use (424) 424
analysis (420) 420
multicenter (420) 420
expression (417) 417
treatment outcome (411) 411
research (400) 400
pd-1 blockade (389) 389
advanced melanoma (386) 386
lymphocytes (379) 379
lung cancer, non-small cell (377) 377
lung neoplasms - drug therapy (372) 372
immunotherapy - methods (369) 369
prognosis (354) 354
biomarkers (346) 346
drug therapy (344) 344
non-small cell lung cancer (343) 343
melanoma - drug therapy (340) 340
antibodies, monoclonal - adverse effects (336) 336
pd-1 protein (329) 329
immune checkpoint inhibitors (320) 320
aged, 80 and over (317) 317
metastases (309) 309
medicine & public health (300) 300
medical research (298) 298
mutation (294) 294
adverse events (292) 292
untreated melanoma (287) 287
cell death (286) 286
medicine, research & experimental (279) 279
carcinoma, non-small-cell lung - drug therapy (277) 277
antibody (276) 276
antineoplastic agents, immunological - therapeutic use (276) 276
health aspects (267) 267
t-cells (266) 266
pd-l1 protein (265) 265
programmed cell death 1 receptor - immunology (260) 260
pharmacology & pharmacy (259) 259
ligands (258) 258
anti-pd-1 (257) 257
immunohistochemistry (256) 256
lung neoplasms - pathology (256) 256
t cells (256) 256
medical prognosis (251) 251
usage (247) 247
checkpoint inhibitors (244) 244
trial (240) 240
atezolizumab (237) 237
animals (236) 236
case report (234) 234
antibodies (229) 229
antineoplastic agents - adverse effects (229) 229
carcinoma (229) 229
development and progression (229) 229
nsclc (224) 224
combined nivolumab (220) 220
review (220) 220
neoplasms. tumors. oncology. including cancer and carcinogens (217) 217
immune checkpoint inhibitor (215) 215
lymphocytes t (215) 215
toxicity (213) 213
b7-h1 antigen - antagonists & inhibitors (212) 212
cytotoxicity (212) 212
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4778) 4778
French (79) 79
German (58) 58
Japanese (25) 25
Russian (19) 19
Korean (12) 12
Spanish (9) 9
Chinese (6) 6
Czech (5) 5
Italian (4) 4
Polish (3) 3
Danish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ophthalmology, ISSN 0161-6420, 07/2019, Volume 126, Issue 7, pp. 1058 - 1062
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2018, Volume 29, Issue 4, pp. 1065 - 1066
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1668 - 1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited... 
CRITERIA | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
The Oncologist, ISSN 1083-7159, 12/2018, Volume 23, Issue 12, pp. e159 - e161
Central nervous system metastasis in non‐small cell lung cancer remains a therapeutic challenge and confers a poor prognosis. Here we describe a patient with... 
ONCOLOGY | NIVOLUMAB
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | PEMBROLIZUMAB | Rapid Communications
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2017, Volume 28, Issue 12, pp. 3104 - 3106
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 255 - 264
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines... 
PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | IMMUNOTHERAPY | SAFETY | DOCETAXEL
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 12, pp. 1031 - 1031
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 11, pp. 2895 - 2896
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 2, pp. 434 - 435
Journal Article
Acta Oncologica, ISSN 0284-186X, 07/2019, Volume 58, Issue 7, pp. 962 - 966
Introduction: Phase III studies of PD-1 inhibitors have demonstrated remarkable improvements in the survival of patients with metastatic melanoma (MM). If... 
BRAF | ONCOLOGY | NIVOLUMAB | IPILIMUMAB
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2019, Volume 14, Issue 1, pp. e5 - e7
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 04/2018, Volume 32, Issue 4, pp. e124 - e126
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 01/2017, Volume 44, Issue 1, pp. 59 - 62
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 3, pp. 989 - 999
Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI).... 
MICROENVIRONMENT | ONCOLOGY | NIVOLUMAB | PD-L1 EXPRESSION | ADENOCARCINOMA
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 09/2015, Volume 38, Issue 9, pp. 473 - 473
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2019, Volume 14, Issue 3, pp. 494 - 502
With increasing use of immune checkpoint inhibitors (ICIs) for advanced NSCLC, there is increasing recognition of immune-related adverse events associated with... 
ONCOLOGY | NIVOLUMAB | RESPIRATORY SYSTEM | DOCETAXEL
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.